000303504 001__ 303504
000303504 005__ 20250815114533.0
000303504 0247_ $$2doi$$a10.1093/noajnl/vdaf110
000303504 0247_ $$2pmid$$apmid:40800122
000303504 0247_ $$2pmc$$apmc:PMC12342540
000303504 037__ $$aDKFZ-2025-01695
000303504 041__ $$aEnglish
000303504 082__ $$a610
000303504 1001_ $$0P:(DE-He78)d95caa04c2f0929079004f117746b1e1$$aFischer, Tom$$b0$$eFirst author$$udkfz
000303504 245__ $$aCerebrospinal fluid liquid biopsy guides differential diagnosis of relapsed medulloblastoma versus secondary glioma: A case report of a pediatric patient enrolled on a PDGFRA inhibitor trial.
000303504 260__ $$aOxford$$bOxford University Press$$c2025
000303504 3367_ $$2DRIVER$$aarticle
000303504 3367_ $$2DataCite$$aOutput Types/Journal article
000303504 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1755241866_8666
000303504 3367_ $$2BibTeX$$aARTICLE
000303504 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303504 3367_ $$00$$2EndNote$$aJournal Article
000303504 500__ $$a#EA:B062#LA:B062#
000303504 520__ $$aLiquid biopsies have the potential to substantially transform clinical oncology, but their technical applicability and clinical utility in pediatric neuro-oncology remain to be explored. Here, we present a case of a medulloblastoma patient in which a cerebrospinal fluid liquid biopsy provided an accurate molecular tumor classification of a secondary glioma during follow-up. Using Nanopore sequencing and low-coverage whole genome sequencing pipelines optimized for cell-free DNA, the liquid biopsy revealed a PDGFRA amplification and DNA methylation-based tumor classification consistent with a secondary glioma. These findings guided the tumor board's differential diagnosis of medulloblastoma relapse versus secondary glioma. Notably, the rapid turnaround time of the Nanopore sequencing results enabled timely preparation for enrollment in a PDGFRA inhibitor trial while awaiting confirmatory results from the tissue biopsy. This case exemplifies the advancing frontier of liquid biopsies and provides the rationale for prospective implementation in larger case series and clinical trials in pediatric neuro-oncology.
000303504 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000303504 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303504 650_7 $$2Other$$acell-free DNA
000303504 650_7 $$2Other$$acerebrospinal fluid liquid biopsy
000303504 650_7 $$2Other$$amolecular biomarkers
000303504 650_7 $$2Other$$apediatric neuro-oncology
000303504 650_7 $$2Other$$asecondary glioma
000303504 7001_ $$0P:(DE-He78)5100059e746b377e2e0a37c0e24f6bf7$$aMaass, Kendra$$b1$$udkfz
000303504 7001_ $$00000-0002-1373-8130$$aSchoof, Melanie$$b2
000303504 7001_ $$aPuranachot, Pitithat$$b3
000303504 7001_ $$0P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aSievers, Philipp$$b4$$udkfz
000303504 7001_ $$0P:(DE-He78)7cc443f837a5f3c1a6cf70501e440079$$aMontigel, Sophia$$b5$$udkfz
000303504 7001_ $$00009-0002-4965-8260$$aFluhr, Theresa$$b6
000303504 7001_ $$00000-0003-0146-8943$$aEl Damaty, Ahmed$$b7
000303504 7001_ $$aSeitz, Angelika$$b8
000303504 7001_ $$aHarrabi, Semi$$b9
000303504 7001_ $$0P:(DE-He78)2f592d9d8339bee07cca3956b7472b61$$aSchramm, Kathrin$$b10$$udkfz
000303504 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b11$$udkfz
000303504 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b12$$udkfz
000303504 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b13$$udkfz
000303504 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b14$$udkfz
000303504 7001_ $$0P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271$$avan Tilburg, Cornelis Martinus$$b15$$udkfz
000303504 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b16$$udkfz
000303504 7001_ $$00000-0002-8731-1121$$aSchüller, Ulrich$$b17
000303504 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b18$$eLast author$$udkfz
000303504 773__ $$0PERI:(DE-600)3009682-0$$a10.1093/noajnl/vdaf110$$gVol. 7, no. 1, p. vdaf110$$n1$$pvdaf110$$tNeuro-oncology advances$$v7$$x2632-2498$$y2025
000303504 909CO $$ooai:inrepo02.dkfz.de:303504$$pVDB
000303504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d95caa04c2f0929079004f117746b1e1$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000303504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5100059e746b377e2e0a37c0e24f6bf7$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000303504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000303504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7cc443f837a5f3c1a6cf70501e440079$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000303504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2f592d9d8339bee07cca3956b7472b61$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000303504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000303504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000303504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000303504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000303504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000303504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000303504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000303504 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000303504 9141_ $$y2025
000303504 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOL ADV : 2022$$d2024-12-18
000303504 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000303504 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000303504 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-03T10:37:56Z
000303504 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-03T10:37:56Z
000303504 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-03T10:37:56Z
000303504 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000303504 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-18
000303504 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000303504 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000303504 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000303504 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000303504 9202_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000303504 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000303504 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000303504 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x2
000303504 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x3
000303504 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x4
000303504 9200_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000303504 980__ $$ajournal
000303504 980__ $$aVDB
000303504 980__ $$aI:(DE-He78)B062-20160331
000303504 980__ $$aI:(DE-He78)HD01-20160331
000303504 980__ $$aI:(DE-He78)B300-20160331
000303504 980__ $$aI:(DE-He78)B360-20160331
000303504 980__ $$aI:(DE-He78)B310-20160331
000303504 980__ $$aUNRESTRICTED